Jinsheng Huang

Jinsheng Huang

Auto-generated profile, based on publicly available information

Jinsheng Huang

Department of Urology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
ZXZecong Xiao
Zecong Xiao
ZSZhenwei Su
Zhenwei Su
SHShisong Han
Shisong Han
JHJinsheng Huang
Jinsheng Huang
LLLiteng Lin
Liteng Lin
XSXintao Shuai
Xintao Shuai
The response to programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) blockade in cancer immunotherapy is limited because of multiple immune evasion mechanisms. Here, a previously unknown strategy is proposed to synergize the nuclear factor κB (NF-κB) inhibition and PD-1 blockade for antitumor immunotherapy. A dual pH-sensitive nanocarrier loading curcumin (CUR) and anti–PD-1 monoclonal antibody (aPD-1) may bind to circulating PD-1+ T cells and then follow their infiltration into the tumor. Furthermore, the nanodrug bound to PD-1+ T cells may be released in the tumor microenvironment, leaving aPD-1 to block PD-1 on T cells and generating a CUR-encapsulated cationic nanodrug that can be easily taken up by tumor cells/tumor associated macrophages (TAMs). Thus, not only the antitumor T cells mediate efficient CUR delivery to tumor but also the efficient CUR delivery promotes the tumor infiltration of antitumor T cells, thereby resulting in effective activation of antitumor immunity.

28 January 2020 in Small
Verified
Journal Article
Closed access
PDF file
ZSZhenwei Su
Zhenwei Su
ZXZecong Xiao
Zecong Xiao
YWYong Wang
Yong Wang
JHJinsheng Huang
Jinsheng Huang
YAYongcheng An
Yongcheng An
XSXintao Shuai
Xintao Shuai

15 January 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
JWJun Wu
Jun Wu
JHJinsheng Huang
Jinsheng Huang
SKSichi Kuang
Sichi Kuang
JCJingbiao Chen
Jingbiao Chen
XLXiaoxia Li
Xiaoxia Li
XSXintao Shuai
Xintao Shuai
Liver fibrosis, as one of the leading causes of liver‐related morbidity and mortality, has no Food and Drug Administration (FDA)‐approved antifibrotic therapy yet. Although microRNA‐29b (miRNA‐29b) and microRNA‐122 (miRNA‐122) have great potential in treating liver fibrosis via regulating profibrotic genes in hepatic stellate cells (HSCs), it is still a challenge to achieve a HSC‐targeted and meanwhile noninvasively trackable delivery of miRNAs in vivo. Herein, a pH‐sensitive and vitamin A (VA)‐conjugated copolymer VA–polyethylene glycol–polyethyleneimine–poly(N‐(N′,N′‐diisopropylaminoethyl)‐co‐benzylamino) aspartamide (T‐PBP) is synthesized and assembled into superparamagnetic iron oxide (SPIO)‐decorated cationic micelle for miRNA delivery. The T‐PBP micelle efficiently transports the miRNA‐29b and miRNA‐122 to HSC in a magnetic resonance imaging‐visible manner, resulting in a synergistic antifibrosis effect via downregulating the expression of fibrosis‐related genes, including collagen type I alpha 1, α‐smooth muscle actin, and tissue inhibitor of metalloproteinase 1. Consequently, the HSC‐targeted combination therapy with miRNA‐29b and miRNA‐122 demonstrates a prominent antifibrotic efficacy in terms of improving liver function and relieving hepatic fibrosis.

23 May 2023 in Nano Letters
Verified
Journal Article
Closed access
HZHuihai Zhong
Huihai Zhong
GCGengjia Chen
Gengjia Chen
TLTan Li
Tan Li
JHJinsheng Huang
Jinsheng Huang
MLMinzhao Lin
Minzhao Lin
XSXintao Shuai
Xintao Shuai

29 May 2019 in ACS Nano
Verified
Journal Article
Closed access
JHJinsheng Huang
Jinsheng Huang
YXYongmin Xu
Yongmin Xu
HXHong Xiao
Hong Xiao
ZXZecong Xiao
Zecong Xiao
YGYu Guo
Yu Guo
XSXintao Shuai
Xintao Shuai

1 February 2016 in Biomaterials
Verified
Journal Article
Closed access
LWLu Wang
Lu Wang
YYYuanyuan Yuan
Yuanyuan Yuan
SLShudong Lin
Shudong Lin
JHJinsheng Huang
Jinsheng Huang
JDJian Dai
Jian Dai
XSXintao Shuai
Xintao Shuai